Clinical Trials
31 trialsNCT07169851 2026-04-22
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Eli Lilly and Company
Phase 2 Recruiting
NCT06904235 2026-03-31
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Helsinn Healthcare SA
Phase 2 Recruiting
NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
NCT01596413 2024-07-26
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
NCT01596426 2024-07-26
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
NCT03204279 2024-06-25
CINV
Helsinn Healthcare SA
Phase 2 Completed
NCT01596400 2024-06-17
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT03649230 2023-08-18
EVOLVE_CINV
Purdue Pharma, Canada
Completed
NCT05272865 2023-02-01
Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC
LaSanta S A S
Phase 1/2 Unknown
NCT05199818 2023-01-20
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Xiamen LP Pharmaceutical Co., Ltd
Phase 3 Unknown
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT01363479 2021-09-22
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT00285051 2020-12-23
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Rafa Laboratories
Phase 2 Terminated
NCT03403712 2020-06-01
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Helsinn Healthcare SA
Phase 3 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT02557035 2018-06-20
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT00601172 2018-01-17
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
GlaxoSmithKline
Phase 3 Completed
NCT00334646 2017-11-17
Cyclophosphamide Drug Interaction Study In Cancer Patients
GlaxoSmithKline
Phase 1 Terminated
NCT00431236 2017-08-22
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
Phase 3 Completed
NCT00440128 2017-08-04
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01366599 2017-05-24
CV Events in Emetogenic Chemotherapy
GlaxoSmithKline
Completed
NCT00684463 2017-05-16
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00687011 2017-05-15
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00092183 2017-05-05
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00092196 2017-05-05
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01887314 2016-01-27
Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy
Helsinn Healthcare SA
Phase NA Completed
NCT02563951 2016-01-08
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Maxinase Life Sciences Ltd.
Phase 1 Completed
NCT00891761 2015-04-17
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
Phase 3 Withdrawn
NCT01339260 2014-11-26
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT00212602 2012-06-14
ONO-7436 Phase II Study in Japan
Ono Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00169572 2010-05-10
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
GlaxoSmithKline
Phase 2 Completed